GNS Healthcare Adds Leading Real World Outcomes and Comparative Effectiveness Experts to Scientific Advisory Board
Dr. James Robins, Dr. Peter Neumann and Dr. Zak Kohane to help guide the company's big data modeling efforts to improve patient outcomes and cost-effectiveness.
Cambridge, Mass. - May 20, 2014 - GNS Healthcare announced today the addition of three premier experts in their respective fields to the Company's scientific advisory board (SAB). These included Dr. James Robins, the Mitchell L. and Robin LaFoley Dong Professor of Epidemiology at the Harvard School of Public Health, Dr. Peter Neumann, Director of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center and Professor at the Tufts University School of Medicine and Dr. Isaac "Zak" Kohane, Director of the Children's Hospital Informatics Program.
"We are thrilled to have Drs. Robins, Neumann and Kohane join our scientific advisory board," said Colin Hill, CEO of GNS Healthcare, "These renowned experts will help guide the application of our machine learning platforms and models to the most important issues facing pharmaceutical health economics and outcomes research in this new era of value-driven pricing and reimbursement. As we continue to partner with payers, providers and the biopharma industry to improve outcomes and reduce treatment costs via data-driven personalized medicine, their experience will prove invaluable."
The principal focus of Dr. Robins' research has been the development of analytic methods appropriate for drawing causal inferences from complex observational and randomized studies with time-varying exposures or treatments.
According to Dr. Robins "Although statistical causal methods have been developed to analyze the complex data sets that form the basis of comparative effectiveness research, nonetheless integration of these causal methods with the powerful big data methods being developed in machine learning has been needed. GNS Healthcare's big data analytics platform integrates causal and machine learning methodologies, thereby producing high level, state of the art, comparative effectiveness analyses."
Dr. Peter Neumann's research has focused on the use of cost-effectiveness analysis in health care decision making, the Food and Drug Administration's regulation of health economic information, and the role of clinical and economic evidence in informing public and private sector health care decisions, including those made by the Medicare program.
Isaac (Zak) Kohane M.D., Ph.D is the director of the Children's Hospital Informatics Program and is the Professor of Pediatrics and Health Sciences and Technology at Harvard Medical School (HMS). He is also the co-Director of the HMS Center for Biomedical Informatics and Director of the HMS Countway Library of Medicine. Dr. Kohane leads multiple collaborations at Harvard Medical School and its hospital affiliates in the use of genomics and computer science to study diseases (particularly cancer and autism) through the perspective of biological development. He also has developed several computer systems to allow multiple hospital systems to be used as "living laboratories" to study the genetic basis of disease while preserving patient privacy. Among these, the i2b2 (Informatics for Integrating Biology and the Bedside) National Computing Center has been deployed at over 100 academic health centers internationally.
GNS Healthcare's current SAB is comprised of leading researchers, clinicians and scientists including Eric Schadt, PhD, Howard L. Weiner, MD, Philip De Jager, MD, PhD, Maria Pia Sormani, PhD, Jeff Hanke, PhD and Robert R. Ruffolo, Jr., PhD. For full information on our SAB click here.
REFS™ (Reverse Engineering and Forward Simulation) is GNS Healthcare's scalable, supercomputer-enabled framework for discovering new knowledge directly from data. REFS™ automates the discovery and extraction of causal network models from observational data and uses high-throughput simulations to generate new knowledge.
About GNS Healthcare
GNS Healthcare is a big data analytics company that empowers payers, providers and pharmaceutical companies to make intelligent data-driven decisions. We unlock knowledge within complex data, enabling personalized, actionable predictions and precision targeting. For 15 years, GNS has been committed to developing and deploying the most sophisticated mathematical and computational platforms to help our partners improve health and reduce costs. For additional news about GNS Healthcare, please click here.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.